EUVIMEDEUVIMED entdecken
Open Access

Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community

Victor V Florea iD, Priya Gajjar, Shi Huang, Jingxian Tang, Shilin Zhao, Megan Davenport, Michael Y Mi iD, Madeleine Haff, Xiaoyu Zhang, Patricia E Miller iD, Ramachandran S Vasan iD, Ching-Ti Liu und 4 weitere

Liver International · 2025

DOI: 10.1111/liv.16147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Victor V Florea und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Cardiorespiratory Fitness, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, American Heart Association, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Individuals with steatotic liver disease (SLD) are at high cardiovascular disease (CVD) risk, but approaches to characterise and mitigate this risk are limited. By investigating relations, and shared metabolic pathways, of hepatic steatosis/fibrosis and cardiorespiratory fitness (CRF), we sought to identify new avenues for CVD risk reduction in SLD.

Methods

In Framingham Heart Study (FHS) participants ( N = 2722, age 54 ± 9 years, 53% women), vibration‐controlled transient elastography (VCTE) was performed between 2016–2019 to assess hepatic steatosis (continuous attenuation parameter [CAP]) and fibrosis (liver fibrosis measure [LSM]). Concurrently, participants underwent maximum effort cardiopulmonary exercise testing (CPET), and metabolomic profiling (201 circulating metabolites) was performed in a subsample ( N = 1268).

Results

Mean BMI was 28.0 ± 5.3, 27% had hepatic steatosis, 7.6% had fibrosis, and peak oxygen uptake (VO 2 ) was 26.2 ± 6.8 mL/kg/min in men and 20.7 ± 6.0 mL/kg/min in women (95% predicted overall). In linear models adjusted for cardiometabolic risk factors, greater CAP and LSM were associated with lower peak VO 2 ( p ≤ 0.002 for all), and the CAP association remained significant after BMI adjustment ( p < 0.0001). We observed shared metabolic architecture of CAP, LSM, and peak VO 2 , with metabolites mediating up to 35% (for CAP) and 74% (for LSM) of the association with peak VO 2 . Metabolite mediators included amino acids and derivatives implicated in cardiometabolic risk and both protective and deleterious lipid species.

Conclusions

Hepatic steatosis and fibrosis are associated with CRF impairment in the community, and these relations are partly mediated by pathways of altered lipid metabolism and general cardiometabolic risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiorespiratory FitnessLiver CirrhosisHumansFemaleMaleMiddle AgedElasticity Imaging TechniquesAgedExercise TestCardiovascular DiseasesFatty LiverAdultNon-alcoholic Fatty Liver DiseaseMetabolomicsOxygen Consumption

Stichwörter der Autor:innen

cardiopulmonary exercise testingmetabolic dysfunction‐associated steatotic liver diseasemetabolismmetabolomicspeak oxygen uptake

Autor:innen und Institutionen

  • Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
  • Cardiovascular Medicine Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Vanderbilt Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
  • Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Section of Gastroenterology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.

ORCID-Profile: Victor V Florea, Michael Y Mi, Patricia E Miller, Ramachandran S Vasan, Gregory D Lewis, Ravi V Shah, Michelle T Long, Matthew Nayor

Förderung

  • NHLBI NIH HHS
  • American Heart Association
  • Gilead Sciences
  • NIDDK NIH HHS
  • School of Medicine, Boston University
  • Echosens
  • Doris Duke Charitable Foundation
  • Clinical and Translational Science Institute, Boston University

Zitieren

APA

Florea, V. V., Gajjar, P., Huang, S., Tang, J., Zhao, S., Davenport, M., Mi, M. Y., Haff, M., Zhang, X., Miller, P. E., Vasan, R. S., Liu, C. T., Lewis, G. D., Shah, R. V., Long, M. T., & Nayor, M. (2025). Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community. Liver International. https://doi.org/10.1111/liv.16147

Vancouver

Florea VV, Gajjar P, Huang S, Tang J, Zhao S, Davenport M, et al. Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community. Liver International. 2025. doi:10.1111/liv.16147

BibTeX
@article{Florea2025,
  author = {Florea, Victor V and Gajjar, Priya and Huang, Shi and Tang, Jingxian and Zhao, Shilin and Davenport, Megan and Mi, Michael Y and Haff, Madeleine and Zhang, Xiaoyu and Miller, Patricia E and Vasan, Ramachandran S and Liu, Ching-Ti and Lewis, Gregory D and Shah, Ravi V and Long, Michelle T and Nayor, Matthew},
  title = {Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.16147}
}
Kostenlos starten →